Sawai Pharmaceutical receives approvals for
8 compounds with 19 strengths of generic drugs

Osaka, Japan – February 15, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today received approvals by the Ministry of Health, Labour and Welfare for 8 compounds with 19 strengths of generic drugs. Among 8 compounds, 6 compounds, Irubesarutan / Amlodipine, Minodronic Acid Hydrate, Lamotrigine, Nalfurafine Hydrochloride, Lanthanum Carbonate and Oseltamivir Phosphate, are approved for the first time as generics.

* ILUAMIX® Combination Tablets LD/HD are Irbesartan and Amlodipine Besilate, and are counted as 1 compounds.

◆Products received approvals are as below;

<table>
<thead>
<tr>
<th>Therapeutic Category</th>
<th>Product Name</th>
<th>Name of Originator drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>Long-acting ARB / Long-acting Ca antagonists</td>
<td>ILUAMIX® Combination Tablets LD [SAWAI]</td>
<td>AIMIX®</td>
</tr>
<tr>
<td></td>
<td>ILUAMIX® Combination Tablets HD [SAWAI]</td>
<td></td>
</tr>
<tr>
<td>Selective histamine H₁ receptor antagonists / Allergic disease treatment</td>
<td>BEPOTASTINE BESILATE OD Tablets 5mg [SAWAI]</td>
<td>TALION® OD Tablets 5mg</td>
</tr>
<tr>
<td></td>
<td>BEPOTASTINE BESILATE OD Tablets 10mg [SAWAI]</td>
<td>TALION® OD Tablets 10mg</td>
</tr>
<tr>
<td></td>
<td>BEPOTASTINE BESILATE Tablets 5mg [SAWAI]</td>
<td>TALION® Tablets 5mg</td>
</tr>
<tr>
<td></td>
<td>BEPOTASTINE BESILATE Tablets 10mg [SAWAI]</td>
<td>TALION® Tablets 10mg</td>
</tr>
<tr>
<td>Osteoporosis treatment agents</td>
<td>MINODRONIC ACID Tablets 1mg [SAWAI]</td>
<td>Bonoteo® Tablets 1mg</td>
</tr>
<tr>
<td></td>
<td>MINODRONIC ACID Tablets 50mg [SAWAI]</td>
<td>Bonoteo® Tablets 50mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RECALBON® Tablets 1mg</td>
</tr>
<tr>
<td>Category</td>
<td>Products</td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td></td>
</tr>
</tbody>
</table>
| Antiepileptic therapeutic agents / Bipolar disorder treatment | RECALBON® Tablets 50mg  
LAMOTRIGINE Tablets 25mg [SAWAI]  
LAMOTRIGINE Tablets 100mg [SAWAI]  
Lamictal® Tablets 25mg  
Lamictal® Tablets 100mg |
| Antiepileptic therapeutic agents             | LAMOTRIGINE Tablets 2mg for Pediatric [SAWAI]  
LAMOTRIGINE Tablets 5mg for Pediatric [SAWAI]  
Lamictal® Tablets 2mg  
Lamictal® Tablets 5mg |
| Oral pruritus improving agents               | NALFURAFINE HYDROCHLORIDE OD Tablets 2.5μg [SAWAI]  
REMITCH® OD TABLETS 2.5μg  
REMITCH® capsules 2.5μg  
NOPICOR® capsules 2.5μg |
| Hyperphosphatemia treatment agents           | LANTHANUM CARBONATE Granules 250mg [SAWAI]  
LANTHANUM CARBONATE Granules 500mg [SAWAI]  
Fosrenol® Granules 250mg  
Fosrenol® Granules 500mg |
| Anti-influenza virus agents                  | OSELTAMIVIR Capsules 75mg [SAWAI]  
OSELTAMIVIR DS 3% [SAWAI]  
TAMIFLU® Capsule 75  
TAMIFLU® Dry Syrup 3% |
| New quinolone antibacterial agent for injectable | LEVOFLOXACIN IV Drip Infusion Bag 500mg/100mL [SAWAI]  
LEVOFLOXACIN IV Drip Infusion 500mg/20mL [SAWAI]  
CRAVIT® INTRAVENOUS DRIP INFUSION BAG 500mg/100mL  
CRAVIT® INTRAVENOUS DRIP INFUSION 500mg/20ml |

◆ Contact information ◆

PR / IR Group, Corporate Strategy Department, Sawai Pharmaceutical Co., Ltd
E-mail: koho@sawai.co.jp